New Parkinson's pill enters first human safety tests

NCT ID NCT07310264

Recruiting now Disease control Sponsor: Vertero Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing whether an experimental oral drug called AX-5006 is safe and tolerable in healthy adults and people with Parkinson's disease. The study involves 84 participants across three parts: single doses in healthy volunteers, multiple daily doses in healthy volunteers, and 28 days of daily dosing in Parkinson's patients. Researchers will monitor side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AX-5006 (also called VT-5006), an oral drug
What this could lead to: If safe and well-tolerated, this could pave the way for larger studies to see if AX-5006 helps control Parkinson's symptoms.
What could go wrong: This is a very early, first-in-human trial focused only on safety, not effectiveness. The drug may not work for Parkinson's or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (HV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS (HV) PARKINSON'S DISEASE (PD)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Center for Human Drug Research
RECRUITING

Leiden, Netherlands

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.